OncoMatch/Clinical Trials/NCT03907826
PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
Is NCT03907826 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including PD-1 blocking antibody and GP for recurrent nasopharyngeal carcinoma.
Treatment: PD-1 blocking antibody · GP — This is a multicenter, randomized controlled, phase III clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemoradiotherapy versus chemoradiotherapy alone in recurrent nasopharyngeal carcinoma patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage RII, RIII, RIVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-tumor Chinese medicine treatment
Treated with anti-tumor Chinese medicine treatment
Cannot have received: PD-1 antibody or other immunotherapy for PD-1/PD-L1 pathway
Have previously treated with PD-1 antibody or other immunotherapy for PD-1/PD-L1 pathway
Lab requirements
Blood counts
wbc count ≥ 3×10e9/l, ne count ≥ 1.5×10e9/l, hgb ≥ 90g/l, plt count ≥ 100×10e9/l
Kidney function
bun/cre ≤ 1.5×uln or endogenous creatinine clearance ≥ 60ml/min (cockcroft-gault formula)
Liver function
alt/ast ≤ 2.5×uln, tbil ≤ 2.0×uln
Cardiac function
nyha class 3 or 4, unstable angina, myocardial infarction within 1 year, or clinically meaningful arrhythmia that requires treatment [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify